

## Prior Authorization Request Form for Antihyperuricemics

## FAX this completed form to (844) 205-3386

OR Mail requests to: Pharmacy Department | 5 River Park Place East, Suite 210 | Fresno, CA 93720 OR Prior authorization may be completed at https://www.covermymeds.com/main/prior-authorization-forms/

I. PROVIDER INFORMATION	II. MEN	BER INFOR	MATION	
Prescriber Name:		Member Name:		
Prescriber Specialty:		Identification #:		
NPI:		Group #:		
Office Contact Name:		Date of Birth:		
Fax #:		Medication Allergies:		
Phone #:				
III. DRUG INFORMATION (One drug	g request per form)			
Drug name and strength:	Dosage Interval (sig):		Qty. per Day:	
IV. REQUIRED DOCUMENTION (Det item must be submitted with prior of		rumentation	demonstrating evidence for each	
Specify diagnosis & diagnosis code releva	ant to this request:	Dx/Dx Code:		
Requests for non-preferred Xanthine member have a history of trial and failur intolerance to the preferred Xanthine Ox <a href="https://papdl.com/preferred-drug-list">https://papdl.com/preferred-drug-list</a> for preferred medications in this class.	e of or contraindication or idase Inhibitor? <i>Refer to</i>	□ Yes	Submit documentation of previous trials/failures, contraindications, and/or intolerances or current use.	
Requests for non-preferred single-ing the member have a history of trial and fa or intolerance to the preferred single-ing <a href="https://papdl.com/preferred-drug-list">https://papdl.com/preferred-drug-list</a> for preferred medications in this class.	ilure of or contraindication gredient Colchicine? <i>Refer to</i>	□ Yes	Submit documentation of previous trials/failures, contraindications, and/or intolerances or current use.	
Requests for non-preferred Antihyper have a history of trial and failure of or co to the preferred single-ingredient Antihy <a href="https://papdl.com/preferred-drug-list">https://papdl.com/preferred-drug-list</a> for preferred medications in this class.	ntraindication or intolerance peruricemic? <i>Refer to</i>		Submit documentation of previous trials/failures, contraindications, and/or intolerances or current use.	
Does the member have a history of contr medication?	aindication to the prescribed	☐ Yes ☐ No	Submit documentation.	
☐ If requesting for daily quantity e <u>Services/Pages/Quantity-Limits</u> information:			v.dhs.pa.gov/providers/Pharmacy- ide supporting	
SUBMIT MEDICAL RECORD INFORMATI	ON FOR EACH APPLICABLE	ITEM.		
KRYSTEXXA:  ☐ If not prescribed by one of the folconsulted: ☐ Recent uric acid level above goal ☐ One of the following: ☐ Continues to have frequent g ☐ Has non-resolving subcutane ☐ Krystexxa will not be used concor	based on American College o out flares (≥ 2 flares/year) ous tophi	f Rheumatolo		

<ul> <li>☐ Member was counseled regarding the following:</li> <li>☐ Appropriate dietary and lifestyle modifications</li> <li>☐ Discontinuation of other medications know to precipitate gout attacks</li> <li>KRYSTEXXA RENEWAL REQUEST:</li> <li>☐ Documentation of improvement in disease severity since initiating Krystexxa, as evidenced by:</li> <li>☐ If not prescribed by one of the following specialist rheumatologist or endocrinologist, please indicate a specialist consulted:</li> <li>☐ Does not have a history of a contraindication to Krystexxa</li> <li>☐ Krystexxa will not be used concomitantly with oral urate-lowering agents</li> </ul>					
IV. ADDITIONAL RATIONALE FOR REQUEST / PERTINENT CLINICAL INFORMATION :					
Appropriate clinical information to support the request on the basis of medical necessity must be submitted.	Provider Signature:	Date:			

Pharmacy Department will respond via fax or phone within 24 hours.

Requests for prior authorization (PA) requests must include member name, ID#, and drug name. Please include lab reports with requests when appropriate (e.g., Culture and Sensitivity; Hemoglobin A1C; Serum Creatinine; CD4; Hematocrit; WBC, etc.)